<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00996424</url>
  </required_header>
  <id_info>
    <org_study_id>2009/464</org_study_id>
    <nct_id>NCT00996424</nct_id>
  </id_info>
  <brief_title>The Effect of Inhaled N-Acetylcysteine Compared to Normal Saline on Sputum Rheology and Lung Function</brief_title>
  <official_title>The Effect of Inhaled N-Acetylcysteine Compared to Normal Saline on Sputum Rheology and Lung Function.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BVSM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inhalation treatment with mucolytics is one of the cornerstones of CF treatment for&#xD;
      respiratory problems.&#xD;
&#xD;
      The efficacy of inhalation treatment with recombinant DNAse and hypertonic saline is well&#xD;
      established. The North American CF foundation reported that there is insufficient evidence&#xD;
      for or against the chronic use of inhaled N-Acetylcysteine (NAC) to improve lung function and&#xD;
      reduce exacerbations .&#xD;
&#xD;
      In vitro tests proved the positive effect of NAC on sputum rheology . Evidence based research&#xD;
      however on the in vivo effect of NAC on visco-elasticity and lung function is rare. There are&#xD;
      only three randomized controlled clinical trials on nebulised NAC, none of them showing a&#xD;
      statistically significant or clinically relevant beneficial effect. Nevertheless at least in&#xD;
      Europe for many years inhalation treatment with NAC is advised. Because of the disgusting&#xD;
      sulphur odour, many patients are reluctant to use this inhalation medication.&#xD;
&#xD;
      We intend to start an open placebo controlled in vivo cross-over study to evaluate the effect&#xD;
      of Acetyl cysteine compared to normal saline on the sputum visco-elasticity and on the short&#xD;
      term effect on lung function.&#xD;
&#xD;
      Sputum producing CF-patients, able to perform lung function tests will be enrolled.&#xD;
&#xD;
      Sputum viscoelasticity will be measured by a controlled-stress rheometer (AR 1000-N;&#xD;
      TA-Instruments, Ghent, Belgium) at 20° C, using a cone-plate geometry 8.&#xD;
&#xD;
      Lung function measurement (FVC, FEV1, FEF 25-75) will be done in a Masterlab body&#xD;
      plethysmograph (Jaeger®) Sputum samples will be collected before lung function test on a&#xD;
      regular control visit. Three ml of NAC or 4 ml of normal saline will be inhaled, afterwards a&#xD;
      second sputum sample will be collected and a control lung function test will be performed.&#xD;
      Visco-elasticity measurements will be done on sputum samples before and after inhalation of&#xD;
      NAC or normal saline. Patients will continue to inhale N-acetylcysteine or normal saline two&#xD;
      times per day for one month. After one month a control lung function and a third sputum&#xD;
      sample will be collected, visco-elasticity and lung function will be measured and compared to&#xD;
      the initial values in both groups and between groups. After a wash-out period of normal&#xD;
      saline inhalations during 2 weeks in both groups, patients in the initial control group will&#xD;
      be asked to switch to inhalation of 3 ml of NAC two times per day and the former NAC group&#xD;
      will continue to inhale two times 4 ml of normal saline during four weeks. After one month&#xD;
      the same measurements of visco-elasticity and lung function tests will be done.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient recruitment.&#xD;
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in visco-elasticity and lung function.</measure>
    <time_frame>after one dose of N-acetylcystein compared to normal saline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in visco-elasticity and lung function.</measure>
    <time_frame>after one month of two doses per day of N-acetylcysteine compared to normal saline.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhalation with N-Acetylcysteine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhalation with normal saline solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylcysteine</intervention_name>
    <description>Inhalation with N-Acetylcysteine</description>
    <arm_group_label>Acetylcysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>Inhalation with normal saline solution</description>
    <arm_group_label>normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who can perform lung function tests and who can produce sputum (&gt; 5 years of&#xD;
             age)&#xD;
&#xD;
          -  (Fe)males between 6-64 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients on the waiting lists for lung transplant.&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Patients can not take part in another 'inhalation'trial for Cystic Fibrosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Van Daele, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>website of the University Hospital Ghent</description>
  </link>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>October 15, 2009</study_first_submitted>
  <study_first_submitted_qc>October 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2009</study_first_posted>
  <last_update_submitted>August 12, 2011</last_update_submitted>
  <last_update_submitted_qc>August 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sabine Van Daele, MD, PhD</name_title>
    <organization>University Hospital Ghent</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

